CZ Biohub Scientific Leadership

Joe DeRisi, Ph.D.

Co-President
Dr. Joseph DeRisi is infusing biomedical research with an inventor’s flair. He led the development of a new diagnostic tool called the Virochip that contains DNA from every known virus that can quickly scan blood or spinal fluid for evidence of infection. A self-described “biologist who is also a serious computer nerd,” his lab at the University of California, San Francisco, is combining an innovative software tool with new genome sequencing technology to develop a prototype diagnostic test that could reveal any infectious disease with near certainty.

Dr. DeRisi employs an interdisciplinary approach to his work, combining genomics, bioinformatics, biochemistry and bioengineering to study parasitic and viral infectious diseases in a wide range of organisms. He was one of the early pioneers of DNA microarray technology and whole genome expression profiling and is nationally recognized for his efforts to make this technology accessible and freely available. Today, he uses this approach to study the activity of the full range of malaria genes and has generated provocative insights in many emerging viral diseases.

Dr. DeRisi is a professor of Biochemistry and Biophysics at the University of California, San Francisco. In 2004, he was chosen for a MacArthur Fellowship. In addition to being a Searle Scholar and a Packard Fellow, Dr. DeRisi has received the Heinz Award in Technology, the Economy and Employment and was named an Eli Lilly and Company Research Award Laureate. He was elected to the American Academy of Arts and Sciences in 2015, and the National Academy of Sciences in 2016. He was also an Investigator of the Howard Hughes Medical Institute from 2005-2016. He received a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz in 1992, and a Ph.D. in Biochemistry from Stanford University in 1999.

 

Steve Quake, D.PHIL.

Co-President
Dr. Stephen Quake’s research is at the nexus of biology, physics and technology development. He has invented many measurement tools for biology, including new DNA sequencing technologies that have enabled rapid analysis of the human genome and microfluidic automation that allows scientists to efficiently isolate individual cells and decipher their genetic code. Dr. Quake is also well known for his work inventing new diagnostic tools, including the first non-invasive prenatal test for Down syndrome and other aneuploidies. His test is rapidly replacing risky invasive approaches such as amniocentesis, and millions of women each year now benefit from this approach. His innovations have helped to radically accelerate the pace of biology and have made medicine safer by replacing invasive biopsies with simple blood tests.

Dr. Quake is the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University. He has received numerous awards for his discoveries and has been elected to several scientific honorary societies, including the National Academy of Sciences, the National Academy of Engineering, The National Academy of Medicine and the National Academy of Inventors. He received a B.S. in Physics and M.S. in Mathematics from Stanford University in 1991 and a doctorate in Theoretical Physics from the University of Oxford in 1994. He began his faculty career at the California Institute of Technology in 1996, where he rose through the ranks to become Professor of Applied Physics and Physics. He joined Stanford in 2005 to help found and lead Stanford’s new Bioengineering department as it grew to nearly two dozen faculty members. He was also an Investigator of the Howard Hughes Medical Institute from 2006-2016.

 

Russ B. Altman, M.D., Ph.D.

Presidents’ Advisory Group
Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, and Biomedical Data Science (and of Computer Science, by courtesy) at Stanford University, and previously chaired its Department of Bioengineering. His primary research interest is the application of computing and informatics technologies to clinical medicine. He is particularly interested in developing methods for understanding drug action at molecular, cellular, organism and population levels and in determining how human genetic variation impacts drug response. Dr. Altman holds an A.B. from Harvard College, an M.D. from Stanford Medical School, and a Ph.D. in Medical Information Sciences from Stanford. He is board certified in Internal Medicine and in Clinical Informatics, and is a fellow of the American College of Physicians, the American College of Medical Informatics, the American Institute of Medical and Biological Engineering, and the American Association for the Advancement of Science. Dr. Altman is an elected member of the National Academy of Medicine (formerly the Institute of Medicine, IOM). He is a past-President, founding board member, and a Fellow of the International Society for Computational Biology, and a past-President of the American Society for Clinical Pharmacology & Therapeutics. He chaired the Science Board advising the FDA Commissioner, and currently serves on the NIH Director’s Advisory Committee, and is Co-Chair of the IOM Drug Forum. As a member of the CZ Biohub Presidents’ Advisory Board, Dr. Altman assists the leadership in formulating and executing an exciting and effective data science and informatics program.

 

Jennifer Doudna, Ph.D.

Presidents’ Advisory Group
Jennifer Doudna, Ph.D. is a professor of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, where she holds the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences, and is a Howard Hughes Medical Institute investigator. She is widely recognized as an expert in RNA structural biology, RNA-mediated gene regulation and, most recently, a co-inventor of CRISPR-Cas9 technology that revolutionized gene editing. Her work has been honored by numerous awards including the NSF Waterman Award, the FNIH Lurie Prize, the Paul Janssen Award for Biomedical Research, the Breakthrough Prize in Life Sciences, the Gruber Prize in Genetics, the Japan Prize in Life Sciences, the Massry Prize, the Heineken Award, the Gairdner Award, the Nakasone Award, and the L’Oreal UNESCO International Prize for Women in Science. Dr. Doudna is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, the American Academy of Arts and Sciences, a Fellow of the American Association for the Advancement of Science, the American Society for Microbiology and the American Association for Cancer Research, and a Foreign Member of the Royal Society. She was named one of Time Magazine’s 100 most influential people in the world in 2015. As a member of the CZ Biohub Presidents’ Advisory Board, Dr. Doudna is focused on helping expand our knowledge of human health and accelerate the development of breakthrough scientific and medical advancements, technologies and therapeutics.

 

Jonathan Weissman, Ph.D.

Presidents’ Advisory Group
Jonathan Weissman received his undergraduate physics degree from Harvard College. After obtaining a Ph.D. in physics from the Massachusetts Institute of Technology, he was a postdoctoral fellow at Yale University School of Medicine. In 1996, Weissman joined the faculty of the University of California-San Francisco in the Department of Cellular and Molecular Pharmacology and was appointed an Investigator at the Howard Hughes Medical Institute in 2000. He has received the Raymond and Beverly Sackler International Prize in Biophysics and the National Academy of Sciences Award for Scientific Discovery, and delivered the 2015 Porter Lecture for the American Society of Cell Biology. Weissman is an elected member of the National Academy of Sciences. His current services include membership on the Scientific Advisory Board for Amgen, the Stowers Institute of Medical Research and Helen Hay Whitney Foundation. He studies how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology. He is also widely recognized for building innovative tools for broadly exploring organizational principles of biological systems. These include ribosome profiling, which globally monitors protein translation, and CRIPSRi/a for controlling the expression of human genes and rewiring the epigenome. At CZ Biohub, Weissman is a member of the Presidents’ Advisory Board with a particular focus on the Cell Atlas Initiative, which seeks to define the internal architecture of cells and contribute to the international effort to define every cell type in the human body.

 

Peter S. Kim, Ph.D.

Lead Investigator, Infectious Disease
Peter Kim carried out his Ph.D. thesis research on protein folding in Robert Baldwin’s laboratory at Stanford University and then became one of the early Whitehead Fellows at MIT’s Whitehead Institute.  Subsequently he held appointments as Professor of Biology at MIT, Member of the Whitehead Institute and Investigator of HHMI.  From 2003 to 2013, he was President of Merck Research Laboratories (MRL) with responsibility for Merck’s research and development activities.  In 2014, he was appointed the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford, where he is also a member of Stanford ChEM-H.  Dr. Kim is an elected member of the National Academy of Sciences, National Academy of Engineering and National Academy of Medicine.  His current service includes the Medical Advisory Board of HHMI and the Council of the National Academy of Sciences.  He is known for discovering how proteins cause viral membranes to fuse with cells.  He has designed novel compounds that stop membrane fusion by HIV and has pioneered efforts to develop an HIV vaccine based on similar principles.  During his tenure at MRL, Merck gained approval for over 20 drugs and vaccines.  At the CZ Biohub, Dr. Kim leads the Infectious Disease Initiative, which aims to explore new approaches and invent new tools for creating diagnostic tests, drugs, vaccines and rapid-response strategies to support the global fight against both existing and newly emerging infectious diseases.

 

Lubert Stryer, M.D.

Senior Advisor
Lubert Stryer is the Winzer Professor of Cell Biology, Emeritus, at Stanford University. His research over more than four decades has been centered on the interplay of light and life. Dr. Stryer’s laboratory discovered the primary stage of amplification in vision and elucidated the G-protein cascade that generates a neural signal in visual excitation. He has developed new fluorescence techniques, as exemplified by fluorescence resonance energy transfer as a spectroscopic ruler. He played a key role at Affymax and Affymetrix in devising novel optical techniques for generating high-density peptide and DNA arrays; he is a co-inventor of the DNA chip. Dr. Stryer authored four editions of Biochemistry, a textbook used widely throughout the world. His honors include the National Medal of Science, and election to the National Academy of Sciences, the American Philosophical Society, and the American Academy of Arts and Sciences.  As a Senior Adviser to CZ Biohub, Dr. Stryer is especially interested in stimulating interactions between CZ Biohub Investigators and major CZ Biohub programs such as the Cell Atlas Initiative and the Infectious Disease Initiative.

Scientific Advisory Board

Sangeeta Bhatia, M.D., Ph.D.

MIT

 

 

Don Ganem, M.D.

Global Head of Infectious Diseases Research and Vice President, Novartis Institutes for Biomedical Research

 

 

Richard Lifton, M.D., Ph.D.

President, Rockefeller University

 

 

Robert Tjian, Ph.D.

Howard Hughes Medical Institute and the University of California, Berkeley